Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for CVS Health (NYSE:CVS) Stock

CVS Health (NYSE:CVS) had its target price raised by Deutsche Bank Aktiengesellschaft from $88.00 to $92.00 in a research note issued to investors on Thursday, MarketBeat.com reports. The firm currently has a “buy” rating on the pharmacy operator’s stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential upside of 1.66% from the company’s current price.

CVS has been the topic of several other research reports. TD Cowen reaffirmed a “buy” rating on shares of CVS Health in a research note on Friday, March 13th. Barclays raised their price target on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a report on Thursday. Argus lowered their price objective on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, January 28th. Robert W. Baird lifted their target price on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Finally, HSBC upped their price target on shares of CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Tuesday. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $95.92.

CVS Health Trading Up 3.6%

NYSE CVS opened at $90.50 on Thursday. The firm’s 50 day moving average price is $76.86 and its two-hundred day moving average price is $78.03. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.63 and a current ratio of 0.87. CVS Health has a twelve month low of $58.35 and a twelve month high of $90.89. The stock has a market cap of $115.47 billion, a price-to-earnings ratio of 39.87, a PEG ratio of 0.88 and a beta of 0.60.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter last year, the firm posted $2.25 earnings per share. CVS Health’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts anticipate that CVS Health will post 7.43 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after acquiring an additional 1,824,424 shares during the period. Capital World Investors increased its stake in shares of CVS Health by 2.1% in the third quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after purchasing an additional 1,419,575 shares during the period. State Street Corp lifted its position in shares of CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares during the last quarter. Capital International Investors boosted its stake in CVS Health by 3.4% during the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock valued at $2,189,793,000 after purchasing an additional 900,153 shares during the period. Finally, Invesco Ltd. grew its holdings in CVS Health by 3.2% in the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after buying an additional 760,579 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS beat Wall Street expectations on Q1 earnings and revenue, reporting about $2.9 billion in profit, with improved Aetna profitability helping drive the upside. The company also raised its 2026 outlook, which investors are reading as a sign that the turnaround is gaining traction. CVS Raises 2026 Outlook As Shares Jump 9.8%
• Positive Sentiment: Several brokerages lifted price targets on CVS, including UBS to $100, Truist to $102, and Deutsche Bank to $92, reinforcing the view that recent operating improvements could support more upside from here.
• Positive Sentiment: Analysts and media reports highlighted improving Medicare Advantage metrics, better medical benefit ratios, and operational efficiencies, suggesting CVS’s health insurance business is moving back toward its longer-term margin targets.
• Positive Sentiment: Commentary from investors and media noted that CVS’s prescription volume and pharmacy operations remain solid, while biosimilar and AI initiatives may support long-term cost control and affordability efforts.
• Neutral Sentiment: Pieces discussing Jim Cramer’s prior favorable view on CVS and articles questioning whether the stock is still attractive mainly reinforce sentiment around the name, but do not add new fundamental information.
• Negative Sentiment: Some articles pointed to ongoing structural pressure in the PBM business and the risk that temporary insurance profit strength may not fully offset longer-term margin challenges.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.